KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Clinical trial NCT05906524 · UNKNOWN
Trial details
- NCT number
- NCT05906524
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-15
- Primary completion
- 2025-04-30
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.